Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

ur Phase II trial testing bavituximab and docetaxel in advanced breast cancer patients. Our anti-viral program received global attention with a publication in the leading journal Nature Medicine highlighting the broad anti-viral potential of bavituximab and other anti-PS antibodies, and we were also awarded a broad U.S. patent covering anti-viral applications of antibodies that directly target PS. These developments, following a major government contract award last quarter to study bavituximab in viral hemorrhagic fever infections, have established our PS-targeting anti-viral platform as an approach that could represent a completely new class of drugs for the treatment of life-threatening viral infections. We look forward to reporting continued progress in our anti-PS programs in the coming months, as well as providing an update on progress in our Cotara(R) clinical program."

Mr. King continued, "Our Avid manufacturing subsidiary continued to expand its client base during the quarter and increased its manufacturing capacity with the addition of an innovative single-use bioreactor system, which should allow Avid to meet the growing demand for its cell culture production services using state-of-the-art, cost-effective technology. Avid revenues recorded this quarter were lower than last year's as a result of the timing of shipments of finished product to customers, but based on product now being readied for shipping and our backlog of orders in hand, we expect robust revenue growth from Avid over the remainder of the fiscal year, with revenues in the third quarter of FY 2009 estimated at upwards of $5 million."

Mr. King concluded, "Despite the turmoil in the global financial markets, we have never been more optimistic about the potential of our lead drug candidates. The encouraging progress in our clinical programs to date and increasing scientific recognition of the promise of our innovative technology have already
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... of Columbia now have a total of 500 confirmed cases ... infecting children since the summer, U.S. health officials reported ... in recent weeks, but it,s not clear what role -- ... said. Health officials are also trying to determine if ...
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... and neck cancer that targets multiple peptides (parts of ... ,The researchers created the vaccine to ... mutated in most cancers and associated with poor clinical ... expresses unaltered, or "wild-type," p53 peptides in tumors. When ...
... critical genetic factor in the control of many aspects ... a genetic factor// , called a microRNA, in animal ... differentiation and development. ,MicroRNAS, or miRNAs, ... fine-tune levels of important proteins in cells. To learn ...
... was keenly interested in Buddhism and traveled to India in pursuit ... of 93. ,Born in 1913, Roaf spent his early ... the age of 13 and received a further scholarship in 1931 ... ,In 1934 Roaf's parents moved from London to Liverpool where he ...
... a universal problem. With a view to conserve water, ... the country.// ,In a press release the government ... India is about 1170 mm. However, there is very ... release further said that there had been considerable progress in ...
... Lebanon, a Mediterranean country, is considered notoriously image-conscious. It may ... militants// clashing fiercely all the time. ,But the ... ,Only that should explain why the Fist National Bank ... surgery. ,Its website dubs the 'plastic surgery loans' ...
... series of facts is one thing, understanding the big ... that// relational memory -- the ability to make logical ... is dependent on taking a break from studies and ... sleep. ,Led by researchers at Beth Israel ...
Cached Medicine News:Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Scientists Identify Critical Gene Factor in Heart Development 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 3
(Date:10/2/2014)... 2014   Mast Therapeutics, Inc. (NYSE MKT: ... Edwin L. Parsley , D.O. has joined the Company ... Dr. Parsley has been actively engaged with ... February 2014.  He has served as Mast,s interim Chief ... Officer of Aires since April 2011.  Dr. Parsley previously ...
(Date:10/2/2014)... Oct. 1, 2014   Intarcia Therapeutics, Inc. ... four phase 3 clinical trials for ITCA 650 (exenatide, ... subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was a ... efficacy and safety of ITCA 650 in patients with ... 650 to be significantly superior to placebo for both ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: